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and time dependent variables. Patient characteristics are
age, gender, severity, being prone to side effects and the
potential to be dangerous. Variables changing in time are
outpatient visits, being in a psychotic episode, symptom
score, treatment, compliance, having side effects and
treatment location. Dependencies are taken into account.
Costs are calculated guided by visits, medication and
location. Outcomes are expressed in terms of the number
and duration of psychotic episodes and the cumulative
PANSS-score. Information on treatment alternatives,
transition probabilities, model structure and health care
utilisation was derived from literature and an expert
panel. RESULTS: It is estimated that ﬁrst-line treatment
with long-acting risperidone is economically dominant
over the alternatives. Per 1000 patients, it is estimated to
prevent approximately 200 and 410 relapses in ﬁve years
compared to scenario 1 and 3. Correspondingly, it is 
estimated to save €15,115 and €6,972 per patient. 
Sensitivity analyses show that the conclusion of economic
dominance is very robust. CONCLUSION: Long-acting
risperidone combines additional effectiveness with cost
savings in patients with a high probability of being 
non-compliant, and should be preferred ﬁrst-line treat-
ment over oral atypicals and conventional depots.
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OBJECTIVE: To estimate resource use and direct medical
costs associated with treatment of Bipolar I Disorder
(BPDI) and Bipolar II Disorder (BPDII) episodes in the
UK. METHODS: A retrospective chart review was con-
ducted covering 19 months of observations on a sample
of 134 UK patients aged 18 years or over (average age
48.4 years) diagnosed with Bipolar Disorder. RESULTS:
Patients with BPDI experienced an average of 1.11
episodes per year whilst BPDII patients experienced 1.21
episodes per year. The yearly average direct cost for
patients who experienced at least one episode during the
study period was £7,714 for BPDI patients (n = 68) and
£2,980 for BPDII patients (n = 25). There were 103 
hospitalisations during the study period and these 
hospitalisations formed the major component of the total
treatment costs with a yearly average hospitalisation cost
of £6,280 for BPDI patients and £1,636 for BPDII
patients. The average yearly drug cost for BPDI patients
was found to be £383 (5% of total cost) and £194 (6.5%
of total cost) for BPDII patients. Manic Episodes required
twice as many hospitalisations per episode and were 
associated with a longer length of stay in hospital com-
pared with Depressive Episodes. The average length of
stay in hospital was 65 days for Manic, 46 days for
Mixed and 36 days for Depressive Episodes. The average
hospital cost was found to be £7,015 for a Manic
Episode, £4,574 for a Mixed Episode and £3,787 for a
Depressive Episode. CONCLUSIONS: The average treat-
ment cost of a BPDI patient was found to be more than
twice the cost of a BPDII patient. The cost difference is
driven by the ﬁnding that Manic Episodes required more
hospitalisations and were associated with a longer length
of hospital stay compared with Mixed or Depressive
Episodes.
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OBJECTIVES: Currently in the Netherlands a ran-
domised clinical trial is executed to compare two 
outpatient psychotherapies for patients with Borderline
Personality Disorder (BPD). The goal of the present study
was to calculate the cost-of-illness (COI) of BPD for
Dutch Society. METHODS: We used a prevalence-based
approach, which takes into account total yearly costs of
all patients who are diagnosed with BPD at a certain point
in time. COI was calculated both top-down and bottom-
up. For top-down calculation, prevalence ﬁgures from
existing registrations and costs of the Dutch health care
system from government publications were used. Baseline
cost interviews of 88 BPD-patients in the trial were used
to estimate bottom-up COI. BPD was deﬁned according
to ICD-9 and ICD-10 (top-down) and DSM-IV (bottom-
up) classiﬁcations. RESULTS: Based on literature, 
prevalence of BPD in the Dutch general population was
estimated at 1.1%. For all cost items, large differences
arise between the bottom-up and the top-down approach.
Total yearly societal are €200,184,828 top-down, and 16
times as high €3,258,240,100 for bottom-up. Healthcare
costs represent 0.03% and 1.03% of total Dutch health
care expenditure, respectively. CONCLUSION: Our
results show large differences between the two methods.
The top-down ﬁgure probably is an underestimation of
true costs due to incomplete registrations. On the other
hand, the bottom-up patient group may not be represen-
tative of the Dutch BPD population because of the in-en
exclusion criteria used in the trial, which exclude the very
mild and the very severe cases. In conclusion, we recom-
mend to assess COI and prevalence in a combined design.
First, prevalence in the general population is assessed.
Subsequently, those subjects diagnosed with the disease
under study should be followed, receiving care as usual,
in order to determine COI. This is the only way to match
bottom-up patient group and total population.
